I-Mab (IMAB)
NASDAQ: IMAB
· Real-Time Price · USD
0.89
-0.05 (-5.32%)
At close: May 01, 2025, 3:56 PM
0.87
-2.10%
After-hours: May 01, 2025, 04:09 PM EDT
-5.32% (1D)
| Bid | 0.87 |
| Market Cap | 72.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 16.41M |
| EPS (ttm) | -0.62 |
| PE Ratio (ttm) | -1.44 |
| Forward PE | -0.43 |
| Analyst | Buy |
| Ask | 0.94 |
| Volume | 28,523 |
| Avg. Volume (20D) | 229,793 |
| Open | 0.90 |
| Previous Close | 0.94 |
| Day's Range | 0.89 - 0.91 |
| 52-Week Range | 0.59 - 2.00 |
| Beta | 1.39 |
About IMAB
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Pha...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 17, 2020
Employees 32
Stock Exchange NASDAQ
Ticker Symbol IMAB
Website https://www.i-mabbiopharma.com
Analyst Forecast
According to 2 analyst ratings, the average rating for IMAB stock is "Buy." The 12-month stock price forecast is $5.5, which is an increase of 517.56% from the latest price.
Stock Forecasts3 months ago
+11.97%
I-Mab shares are trading higher. The stock may be ...
Unlock content with
Pro Subscription
